Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRVANA
2023-504955-28-01Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in sleep disorder comparing Elinzanetant with Placebo (2 arms). Primary endpoint: Change from baseline in WASO at Week 4 as measured by polysomnography. Started Mar 2024; status: completed.
02
Drugs
elinzanetant
03
Conditions
sleep disorder
Beyond the preview
Go deeper on 2023-504955-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504955-28-01.